Recently, various executives have taken part in insider selling activity for the stocks of Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Kite Pharma Inc (NASDAQ:KITE), Agios Pharmaceuticals Inc (NASDAQ:AGIO), and Pacira Pharmaceuticals Inc (NASDAQ:PCRX).

Intercept Pharmaceuticals Inc

CMO David Shapiro unloaded 4,272 Intercept Pharmaceuticals shares (18.98% of total stake), valued at $894,429, in a transaction dated August 17. The shares were sold via automatic sale program. Shapiro now holds 18,233 of the company’s shares that are valued at $3,766,573.

Click Here to see the performance of Intercept Pharmaceuticals insiders.

Kite Pharma Inc

VP of Clinical Development Jeffrey Wiezorek sold 9,000 Kite Pharma shares, valued at $547,820, in three transactions dated August 17. The shares were sold via automatic sale program. Wiezorek now holds 5,218 of the company’s shares that are valued at $317,614.

VP of Regulatory Affairs Rizwana Sproule unloaded 9,567 shares, valued at $582,407, on August 17.  The shares were sold via automatic sale program. Sproule now holds 1,695 of the company’s shares that are valued at $103,186.

Chief Scientific Officer Margo Roberts disposed of 6,145 shares, valued at $374,236. The shares were sold via automatic sale program. Roberts now holds 999 of the company’s shares that are valued at $60,840.

Click Here to see the performance of Kite Pharma insiders.

Agios Pharmaceuticals Inc

Chief Operating Officer John Duncan Higgons unloaded 20,000 Agios Pharmaceuticals shares (13.17% of total stake), valued at $1,844,800, in a transaction dated August 17. The shares were sold via automatic sale program. Higgons now holds 131,835 of the company’s shares that are valued at $12,171,007.

According to TipRanks.com, which measures corporate insiders’ success based on their transactions, John Duncan Higgons has an average return of 76.2% and a 60% success rate. Higgons is ranked #957 out of 33584 corporate insiders.

Director Lewis Clayton Cantley on August 18 unloaded 9,704 shares (3.08% of total stake), valued at $921,322, in multiple transactions date August 17-18. The shares were sold via automatic sale program. Cantley now holds 152,706 of the company’s shares that are valued at $14,097,818.

Click Here to see the performance of Agios Pharmaceuticals insiders.

Pacira Pharmaceuticals Inc

Director Paul Hastings disposed of 3,000 Pacira shares (51.26% of total stake), valued at $180,060, in a transaction dated August 17. The shares were sold via automatic sale program. Hastings now holds 2,853 of the company’s shares that are valued at $181,422.

Click Here to see the performance of Pacira Pharmaceuticals insiders.